JADE-001 is a potential best-in-class monoclonal antibody designed to block the APRIL (“A PRoliferation Inducing Ligand”) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE-001 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.
Understanding IgA Nephropathy and JADE-001’s Role in Treatment
What is IgA Nephropathy?
Immunoglobulin A (IgA) nephropathy, or IgAN, is a chronic autoimmune disease in which an abnormal form of IgA (a type of antibody produced by the body) is deposited in the kidney and causes kidney damage. Over time, kidney function can decline and may lead to kidney failure requiring dialysis or kidney transplant. IgAN is often diagnosed in young adulthood, and there are currently no approved treatments for IgAN that reduce the abnormal form of IgA and stabilize kidney function.
What is APRIL?
APRIL, short for “A PRoliferation Inducing Ligand,” is a protein in the body that is necessary for immune cells to make IgA antibodies. Too much APRIL can lead to the overproduction of IgA, including the abnormal form that is harmful to the kidney. By targeting APRIL, Jade scientists are working to treat the initiating cause of the disease.
How JADE-001 Works
JADE-001 is an experimental therapy designed to reduce the production of harmful IgA by blocking APRIL. JADE-001 has the potential to provide advantages over other APRIL therapies currently in development by combining higher potency and longer duration of action.
These improvements aim to deliver a more effective and patient-friendly treatment by reducing:
Harmful IgA production
Directly lowering the excess IgA that damages the kidneys.
Signs and symptoms
Associated with progressive kidney damage and the likelihood of kidney failure.
Treatment frequency
Possibly allowing patients to receive treatment only several times a year, making it more convenient for those needing long-term care.
With its unique design, JADE-001 aims to tackle IgAN at its source while offering enhanced convenience and effectiveness.
Potential disease-modifying MoA
Potential to deplete harmful IgA, avoids broad immunosuppression
More convenient dosing
Enabled by half-life extension technology
Potential best-in-class clinical activity
Designed for superior potency, half-life with potential to maximize clinical remission